ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

In findings from the phase III JAVELIN Gastric 300 trial, survival was not improved with the anti–PD-L1 agent avelumab compared with chemotherapy in previously treated patients with gastric or gastroesophageal junction adenocarcinoma.
 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.